Therapeutic targets and biomarkers in IBD

摘要

The present invention relates to a method of treating chronic enteritis and / or inflammatory bowel disease by administering an antagonist of oncostatin-M (OSM) and / or OSM receptor-β (OSMR). The invention also relates to a method for diagnosing or prognosing chronic enteritis and / or inflammatory bowel disease in an individual, and a method for predicting whether an individual will respond to anti-TNFα therapy. The method includes measuring OSM and / or OSMR in the individual.